MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Journal of Hematology and Oncology' source. Sun, 21 Mar 2010 15:13:13 +0100 http://www.medworm.com/index.php?rid=3360868&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F3%2F1%2F10 Conclusions: The RRM1 polymorphism 37C->A correlated with PFS in NSCLC patients treated with gemcitabine-based chemotherapy. No significant correlation was found between PBMC RRM1 mRNA expression and the efficacy of gemcitabine. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=3360868 Sat, 13 Mar 2010 00:00:00 +0100 3360868 http://www.medworm.com/index.php?rid=3356156&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F3%2F1%2F9 Conclusions: Canfosfamide in combination with PLD is well tolerated and active in platinum and paclitaxel refractory or resistant ovarian cancer. A randomized phase 3 study was conducted based on this supportive phase 2 study.Trial Registration: This study was registered at www.clinicaltrials.gov: NCT00052065. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=3356156 Thu, 11 Mar 2010 00:00:00 +0100 3356156 http://www.medworm.com/index.php?rid=3264442&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F3%2F1%2F8 The Ras-dependent Raf/MEK/ERK1/2 mitogen-activated protein (MAP) kinase signaling pathway is a major regulator of cell proliferation and survival. Not surprisingly, hyperactivation of this pathway is frequently observed in human malignancies as a result of aberrant activation of receptor tyrosine kinases or gain-of-function mutations in RAS or RAF genes. Components of the ERK1/2 pathway are therefore viewed as attractive candidates for the development of targeted therapies of cancer. In this article, we briefly review the basic research that has laid the groundwork for the clinical development of small molecules inhibitors of the ERK1/2 pathway. We then present the current state of clinical evaluation of MEK1/2 inhibitors in cancer and discuss challenges ahead. (Source: Journal of Hematolo... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=3264442 Thu, 11 Feb 2010 00:00:00 +0100 3264442 http://www.medworm.com/index.php?rid=3256582&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F3%2F1%2F7 Due to the low survival rates from invasive ovarian cancer, new effective treatment modalities are urgently needed. Compelling evidence indicates that the immune response against ovarian cancer may play an important role in controlling this disease. We herein summarize multiple immune-based strategies that have been proposed and tested for potential therapeutic benefit against advanced stage ovarian cancer. We will examine the evidence for the premise that an effective therapeutic vaccine against ovarian cancer is useful not only for inducing remission of the disease but also for preventing disease relapse. We will also highlight the questions and challenges in the development of ovarian cancer vaccines, and critically discuss the limitations of some of the existing immunotherapeutic strat... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=3256582 Wed, 10 Feb 2010 00:00:00 +0100 3256582 http://www.medworm.com/index.php?rid=3241382&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F3%2F1%2F6 Conclusion: Local control and survival following CyberKnife radiosurgery for stage IA NSCLC is exceptional. Early transient increases in tumor SUVmax are likely related to radiation-induced pneumonitis. Tumor SUVmax values return to background levels at 18-24 months, enhancing 18F-FDG PET/CT detection of local failure. The value of18F-FDG PET/CT imaging for surveillance following lung SBRT deserves further study. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=3241382 Thu, 04 Feb 2010 00:00:00 +0100 3241382 http://www.medworm.com/index.php?rid=3237467&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F3%2F1%2F5 Histone deacetylases (HDACs) can regulate expression of tumor suppressor genes and activities of transcriptional factors involved in both cancer initiation and progression through alteration of either DNA or the structural components of chromatin. Recently, the role of gene repression through modulation such as acetylation in cancer patients has been clinically validated with several inhibitors of HDACs. One of the HDAC inhibitors, vorinostat, has been approved by FDA for treating cutaneous T-cell lymphoma (CTCL) for patients with progressive, persistent, or recurrent disease on or following two systemic therapies. Other inhibitors, for example, FK228, PXD101, PCI-24781, ITF2357, MGCD0103, MS-275, valproic acid and LBH589 have also demonstrated therapeutic potential as monotherapy or combi... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=3237467 Thu, 04 Feb 2010 00:00:00 +0100 3237467 http://www.medworm.com/index.php?rid=3190986&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F3%2F1%2F4 We report the complete response to FOLFOX4 therapy of a metastatic urothelial cancer patient, for whom adjuvant gemcitabine plus cisplatin combination chemotherapy had failed. A 54-year-old male patient with urothelial cancer (transitional cell carcinoma) in the right kidney underwent three rounds of adjuvant gemcitabine-cisplatin chemotherapy after extensive radical nephrectomy. However, he had new liver, lung metastases and synchronous two separate primary colon cancer. The lung metastasis lesion was confirmed as a metastatic urothelial cancer via percutaneous transthoracic needle biopsy (PTNB). Liver and lung metastasis lesions disappeared after the 4th cycle of FOLFOX4 chemotherapy. In addition, colon cancer also disappeared after the 8th cycle of FOLFOX4 chemotherapy. The patient was ... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=3190986 Wed, 20 Jan 2010 00:00:00 +0100 3190986 http://www.medworm.com/index.php?rid=3173682&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F3%2F1%2F3 Cancer patients are at increased risk of venous thromboembolism due to a range of factors directly related to their disease and its treatment. Given the high incidence of post-surgical venous thromboembolism in cancer patients and the poor outcomes associated with its development, thromboprophylaxis is warranted. A number of evidence-based guidelines delineate anticoagulation regimens for venous thromboembolism treatment, primary and secondary prophylaxis, and long-term anticoagulation in cancer patients. However, many give equal weight to several different drugs and do not make specific recommendations regarding duration of therapy. In terms of their efficacy and safety profiles, practicality of use, and cost-effectiveness the low-molecular-weight heparins are at least comparable to, and ... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=3173682 Thu, 14 Jan 2010 00:00:00 +0100 3173682 http://www.medworm.com/index.php?rid=3158516&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F3%2F1%2F2 Leser-Trelat syndrome is characterized by the eruptive appearance of multiple seborrheic keratoses in association with underlying malignant disease. Usually, the sign of Leser-Trelat is associated with adenocarcinoma, most frequently of the colon, breast, or stomach, but also of the lung, kidney, liver, and pancreas. Herein, we present a case that we believe is the first report of the sign of Leser-Trelat in association with occult gastric adenocarcinoma and the anamnestic oncologic history of five other multiple primitive cancers. Epidermal growth factor receptor (EGFR) immunohistochemical expression analysis of multiple seborrheic keratoses revealed an intense membranous staining in the basal keratinocytes and in all the upper epidermal layers. Patients with the sign of Leser-Trelat shou... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=3158516 Mon, 11 Jan 2010 00:00:00 +0100 3158516 http://www.medworm.com/index.php?rid=3144016&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F3%2F1%2F1 Conclusions: Prolonged thalidomide therapy enhanced survival rate and less frequently developed serious toxicity in non- transplant multiple myeloma patients. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=3144016 Tue, 05 Jan 2010 00:00:00 +0100 3144016 http://www.medworm.com/index.php?rid=3127673&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F51 We have described a severe combined immunodeficiency (SCID) mouse model that permits the subcutaneous growth of primary human acute leukemia blast cells into a measurable subcutaneous nodule which may be followed by the development of disseminated disease. Utilizing the SCID mouse model, we examined the growth potential of leukemic blasts from 133 patients with acute leukemia, (67 acute lymphoblastic leukemia (ALL) and 66 acute myeloid leukemia (AML)) in the animals after subcutaneous inoculation without conditioning treatment. The blasts displayed three distinct growth patterns: "aggressive", "indolent", or "no tumor growth". Out of 133 leukemias, 46 (34.5%) displayed an aggressive growth pattern, 14 (10.5%) displayed an indolent growth pattern and 73 (55.0%) did not grow in SCID mice. Th... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=3127673 Tue, 29 Dec 2009 00:00:00 +0100 3127673 http://www.medworm.com/index.php?rid=3116906&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F50 The last two decades have witnessed striking advances in our understanding of the biological factors underlying the development of Follicular lymphoma (FL). Development of newer treatment strategies have improved the outlook for many individuals with these disorders; however, with these advances come new questions. Given the long-term survival of patients with FL, drugs with favourable side-effect profile and minimal long-term risks are desired. FL is incurable with current treatment modalities. It often runs an indolent course with multiple relapses and progressively shorter intervals of remission. The identification of new targets and development of novel targeted therapies is imperative to exploit the biology of FL while inherently preventing relapse and prolonging survival. This review... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=3116906 Wed, 23 Dec 2009 00:00:00 +0100 3116906 http://www.medworm.com/index.php?rid=3017842&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F49 Conclusions: Improved bone marrow staging using flow cytometry and immunohistochemistry improves the predictive value of the IPI in patients with DLBCl and should be performed routinely in all cases. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=3017842 Sun, 22 Nov 2009 00:00:00 +0100 3017842 http://www.medworm.com/index.php?rid=2990677&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F48 Pulmonary involvement and skin involvement are rare complications of plasma cell neoplasms. Here we describe what may be the first reported case of a patient with relapse in both of these sites following autologous peripheral blood stem cell transplantation. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2990677 Fri, 13 Nov 2009 00:00:00 +0100 2990677 http://www.medworm.com/index.php?rid=2986739&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F46 Tyrosine kinase inhibitors (TKIs) like dasatinib and nilotinib are indicated as second-line treatment for chronic myeloid leukemia resistant or intolerant to the current first-line TKI imatinib. These are agents are well tolerated, but potent and as such should be monitored for potentially serious side-effects like fluid retention and pleural effusions. Here we present key clinical trial data and safety considerations for all FDA approved TKIs in context for effective management of fluid retention and pleural effusions. Altering the dasatinib regimen from 70 mg twice daily to 100 mg daily reduces the risk of pleural effusion for patients taking dasatinib. Should pleural effusion develop, dasatinib should be interrupted until the condition resolves. Patients with a history of pleural effusi... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2986739 Thu, 12 Nov 2009 00:00:00 +0100 2986739 http://www.medworm.com/index.php?rid=2986738&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F47 Conclusions: To the best of our knowledge, the current study represents the first genomic exploration of PL. The genomic aberration pattern of PL appears to be more similar to that of DLBCL (AIDS-related or non AIDS-related) than to PCM. Our findings suggest that PL may remain best classified as a subtype of DLBCL at least at the genome level. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2986738 Thu, 12 Nov 2009 00:00:00 +0100 2986738 http://www.medworm.com/index.php?rid=2932576&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F45 The mammalian target of rapamycin (mTOR) is an intracellular serine/threonine protein kinase positioned at a central point in a variety of cellular signaling cascades. The established involvement of mTOR activity in the cellular processes that contribute to the development and progression of cancer has identified mTOR as a major link in tumorigenesis. Consequently, inhibitors of mTOR, including temsirolimus, everolimus, and ridaforolimus (formerly deforolimus) have been developed and assessed for their safety and efficacy in patients with cancer. Temsirolimus is an intravenously administered agent approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for the treatment of advanced renal cell carcinoma (RCC). Everolimus is an oral agent that has recen... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2932576 Tue, 27 Oct 2009 00:00:00 +0100 2932576 http://www.medworm.com/index.php?rid=2921794&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F44 Recent studies have suggested that the presence of iron overload prior to stem cell transplantation is associated with decreased survival. Within these studies, the criteria used to define iron overload have varied considerably. Given the lack of consensus regarding the definition of iron overload in the transplant setting, we sought to methodically examine iron status among transplant patients. We studied 78 consecutive patients at risk for transfusion-related iron overload (diagnoses included AML, ALL, MDS, and aplastic anemia) who received either autologous or allogeneic stem cell transplant. Multiple measures of iron status were collected prior to transplantation and examined for their association with survival. Using this data, three potentially prognostic iron measures were identifie... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2921794 Fri, 23 Oct 2009 23:00:00 +0100 2921794 http://www.medworm.com/index.php?rid=2910244&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F43 Conclusion: Protein C levels were significantly lower in immunocompromised patients when compared to immunocompetent patients in severe sepsis and sepsis categories. Our study suggests a plausible role for APC in severely septic immunocompromised patients which need further elucidation. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2910244 Sun, 18 Oct 2009 23:00:00 +0100 2910244 http://www.medworm.com/index.php?rid=2864037&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F42 We report a 30-year-old woman with chronic myeloid leukemia who became pregnant twice successfully. Philadelphia-positive CML in its chronic phase was diagnosed at 16 weeks of her first gestation. At that time, she received no treatment throughout her pregnancy. At 38 weeks of gestation, a normal infant was delivered by cesarean section. At six weeks postpartum, the patient underwent imatinib mesylate therapy but she could not tolerate the treatment. The treatment was then changed to nilotinib at 400 mg orally b.i.d. Two years later, she became pregnant again while she was on nilotinib 200 mg b.i.d. The unplanned pregnancy was identified during her 7.4 weeks of gestation. Because the patient elected to continue her pregnancy, nilotinib was stopped immediately, and no further treatment was ... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2864037 Mon, 05 Oct 2009 23:00:00 +0100 2864037 http://www.medworm.com/index.php?rid=2826138&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F41 DiscussionPlasmacytoma consists of two cohorts of patients with different overall survival; those patients that do not progress to systemic disease and those that develop myeloma. Age > 60 years is associated with disease progression. Identifying patients with systemic disease early in the treatment will permit aggressive and novel treatment strategies to be implemented. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2826138 Wed, 23 Sep 2009 23:00:00 +0100 2826138 http://www.medworm.com/index.php?rid=2780084&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F40 Hereditary spherocytosis (HS) is a genetic disorder of the red blood cell membrane that is characterized clinically by anemia, jaundice and splenomegaly. Evans' syndrome is a clinical syndrome characterized by autoimmune hemolytic anemia (AIHA) accompanied by immune thrombocytopenic purpura (ITP). It results from a malfunction of the immune system that produces multiple autoantibodies specific for red blood cells and platelets (and sometimes other targets). Thus, HS and Evans' syndrome differ in their pathophysiological mechanisms. Here, we report the unusual case of an infant who had both of these diseases concurrently. Possible explanations of this unexpected situation are discussed. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2780084 Wed, 09 Sep 2009 23:00:00 +0100 2780084 http://www.medworm.com/index.php?rid=2764054&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F39 We report a case of rapid respiratory deterioration in a 66-year-old man with clinical presentation, chest radiography, pulmonary function testing and high resolution computed tomography (HRCT) findings consistent with idiopathic interstitial pneumonia, but very poor response to antibiotics and steroids. Lung biopsy showed histopathology consistent with LG that was confirmed by a positive in situ hybridization for Epstein - Barr virus encoded RNA (EBER). The patient was treated with rituximab and combination chemotherapy and showed significant initial clinical improvement with gradual resolution of abnormal findings on imaging. However, the patient developed pancytopenia as a complication of chemotherapy and died secondary to septic shock and renal failure that were refractory to medical m... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2764054 Thu, 03 Sep 2009 23:00:00 +0100 2764054 http://www.medworm.com/index.php?rid=2759821&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F38 Garcinol, harvested from Garcinia indica, has traditionally been used in tropical regions and appreciated for centuries; however its biological properties are only beginning to be elucidated. There is ample data to suggest potent antioxidant properties of this compound which have been used to explain most of its observed biological activities. However, emerging evidence suggests that garcinol could be useful as an anti-cancer agent, and it is increasingly being realized that garcinol is a pleiotropic agent capable of modulating key regulatory cell signaling pathways. Here we have summarized the progress of our current research knowledge on garcinol and its observed biological activities. We have also provided an explanation of observed properties based on its chemical structure and provide... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2759821 Tue, 01 Sep 2009 23:00:00 +0100 2759821 http://www.medworm.com/index.php?rid=2735854&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F37 Conclusion: Our results highlight the potential prognostic significance of selective high abundance serum APPs in patients with EOCa. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2735854 Wed, 26 Aug 2009 23:00:00 +0100 2735854 http://www.medworm.com/index.php?rid=2693387&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F36 Immunomodulatory drugs lenalidomide and pomalidomide are synthetic compounds derived by modifying the chemical structure of thalidomide to improve its potency and reduce its side effects. . Lenalidomide is a 4-amino-glutamyl analogue of thalidomide that lacks the neurologic side effects of sedation and neuropathy and has emerged as a drug with activity against various hematological and solid malignancies. It is approved by FDA for clinical use in myelodysplastic syndromes with deletion of chromosome 5q and multiple myeloma. Lenalidomide has been shown to be an immunomodulator, affecting both cellular and humoral limbs of the immune system. It has also been shown to have anti-angiogenic properties. Newer studies demonstrate its effects on signal transduction that can partly explain its sele... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2693387 Tue, 11 Aug 2009 23:00:00 +0100 2693387 http://www.medworm.com/index.php?rid=2676243&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F34 Ex vivo activation and expansion of lymphocytes for adoptive cell therapy has demonstrated great success. To improve safety and therapeutic efficacy, increased antigen specificity and reduced non-specific response of the ex vivo generated immune cells are necessary. Here, using a complete protein-spanning pool of pentadecapeptides of the latent membrane protein 2A (LMP2A) of Epstein-Barr virus (EBV), a weak viral antigen which is associated with EBV lymphoproliferative diseases, we investigated the phenotype and function of immune effector cells generated based on IFN-gamma or CD137 activation marker selection and dendritic cell (DC) activation. These ex vivo prepared immune cells exhibited a donor- and antigen-dependent T cell response; the IFN-gamma-selected immune cells displayed a dono... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2676243 Wed, 05 Aug 2009 23:00:00 +0100 2676243 http://www.medworm.com/index.php?rid=2676242&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F35 The complete pathological response after primary chemotherapy could represent an important prognostic factor in patients affected by colorectal liver metastases.In recent studies, increasing pCR seems to be correlated with longer overall survival periods and it is recognized as an important prognostic factor in patients treated with pre-operative chemotherapy.The correlation of radiological information on residual neoplastic disease after neoadjuvant treatment, obtained with CT and PET, has to be evaluated; in fact the complete disappearance of liver metastasis on radiological imaging does not always mean a complete disappearance of tumor tissue on histological examination; when it is documented with surgical procedures and confirmed by pathologist's examination, we can consider the comple... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2676242 Wed, 05 Aug 2009 23:00:00 +0100 2676242 http://www.medworm.com/index.php?rid=2655252&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F32 Conclusion: HA is a suitable induction regimen for elderly patients with AML, with relatively low toxicity and reasonable response rate. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2655252 Wed, 29 Jul 2009 23:00:00 +0100 2655252 http://www.medworm.com/index.php?rid=2655251&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F33 Tyrosine Kinase Inhibitors (TKI) have significantly changed the landscape of current cancer therapy. Understanding of mechanisms of aberrant TK signaling and strategies to inhibit TKs in cancer, further promote the development of novel agents.ABT-869, a novel ATP-competitive receptor tyrosine kinase inhibitor is a potent inhibitor of members of the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) receptor families. ABT-869 showed potent antiproliferative and apoptotic properties in vitro and in animal cancer xenograft models using tumor cell lines that were "addicted" to signaling of kinases targeted by ABT-869. When given together with chemotherapy or mTOR inhibitors, ABT-869 showed at least additive therapeutic effects. The phase I trial for ABT-869 wa... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2655251 Wed, 29 Jul 2009 23:00:00 +0100 2655251 http://www.medworm.com/index.php?rid=2642916&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F31 Vorinostat (Zolinza(R)), a histone deacetylase inhibitor, was approved by the US Food and Drug Administration in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. This review summarizes evidence on the use of vorinostat in solid and hematologic malignancies and collated tolerability data from the vorinostat clinical trial program. Pooled vorinostat clinical trial data from 498 patients with solid or hematologic malignancies show that vorinostat was well tolerated as monotherapy or combination therapy. The most commonly reported drug-related adverse events (AEs) associated with monotherapy (n = 341) were fatigue (61.9%), nausea (55.7%), diarrhea (... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2642916 Sun, 26 Jul 2009 23:00:00 +0100 2642916 http://www.medworm.com/index.php?rid=2635800&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F30 Conclusions: Female CML patients at LAC+USC Medical Center present with more significant adverse pre-treatment prognostic factors compared to men, but achieve comparable outcomes. Hispanic patients present with lower risk profile CML and achieve better treatment responses compared to non-Hispanic patients as a whole; these ethnic differences are no longer significant when statistical analysis is limited to patients given imatinib as first-line therapy. Our patients achieve response rates inferior to those of large-scale national studies. This constellation of findings has not been reported in previous studies, and is likely reflective of a unique patient population. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2635800 Thu, 23 Jul 2009 23:00:00 +0100 2635800 http://www.medworm.com/index.php?rid=2616131&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F29 Advances in the treatment of chronic lymphocytic leukemia (CLL) have improved initial overall response (OR) rates, complete response (CR) rates and progression free survival (PFS). Despite these advances, CLL remains incurable with standard therapies. Thus, there remains a need for more effective therapies in both the upfront and relapsed setting, particularly for patients with high-risk cytogenetic abnormalities such as del(11q22) and del(17p13). The 2008 American Society of Hematology (ASH) Annual Meeting featured several presentations which highlighted the ongoing clinical advances in CLL. The benefit of adding rituximab to purine analog therapy in the upfront setting was demonstrated by a large randomized study which showed that the addition of rituximab to fludarabine and cyclophospha... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2616131 Sun, 19 Jul 2009 23:00:00 +0100 2616131 http://www.medworm.com/index.php?rid=2596018&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F28 Conclusions: RIZ1 is a candidate tumor suppressor gene whose expression is decreased in blast crisis. Loss of RIZ1 activity results in decreased apoptosis and differentiation and enhanced proliferation. Together these results suggest that loss of RIZ1 expression will lead to an increase in myeloid blast cell population resulting in CML progression. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2596018 Mon, 13 Jul 2009 23:00:00 +0100 2596018 http://www.medworm.com/index.php?rid=2554236&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F27 We here report a case of rheumatoid arthritis (RA) with acute myeloid leukemia with multilineage dysplasia (AML-MLD) and Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder (T-LPD). A 64-year-old healthy man suffered from arthralgia, and was ultimately diagnosed with RA based on bilateral hand X-rays showing mild swelling and destruction of the MP and PIP joints. Since non-steroidal anti-inflammatory drugs were not effective, prednisolone and bucillamine were administered. After 4 months, his pancytopenia gradually progressed, and bone marrow (BM) examination revealed the presence of AML-MLD. A chemotherapeutic drug regimen including low-dose cytarabine led to nearly complete remission, but several weeks later, high fever and dyspnea suddenly appeared. Computer tomograp... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2554236 Mon, 29 Jun 2009 23:00:00 +0100 2554236 http://www.medworm.com/index.php?rid=2490495&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F26 We describe a rare presentation of acute lymphoblastic leukemia in a young adult male who had vague and minimal symptoms with mild splenomegaly. There was severe eosinophilia along with absence of blasts in the peripheral blood, and 40% blasts with increase in eosinophils in the bone marrow. The blasts were positive for common precursor B cell markers on flow cytometry. The patient had a unique cytogenetic abnormality t(7;12)(q22;p13),-9, not previously described in acute lymphoblastic leukemia. He was categorized as poor risk due to failure to achieve complete remission after induction with UK ALL XII chemotherapy. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2490495 Sat, 20 Jun 2009 23:00:00 +0100 2490495 http://www.medworm.com/index.php?rid=2470612&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F25 Non-prescriptional use of medicinal herbs among cancer patients is common around the world. The alleged anti-cancer effects of most herbal extracts are mainly based on studies derived from in vitro or in vivo animal experiments. The current information suggests that these herbal extracts exert their biological effect either through cytotoxic or immunomodulatory mechanisms. One of the active compounds responsible for the immune effects of herbal products is in the form of complex polysaccharides known as beta-glucans. beta-glucans are ubiquitously found in both bacterial or fungal cell walls and have been implicated in the initiation of anti-microbial immune response. Based on in vitro studies, beta-glucans act on several immune receptors including Dectin-1, complement receptor (CR3) and TL... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2470612 Wed, 10 Jun 2009 04:00:00 +0100 2470612 http://www.medworm.com/index.php?rid=2460190&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F24 Conclusions: Multi-marker immunobead RT-PCR analysis of peripheral blood is a robust assay that is capable of detecting circulating tumour cells in early stage breast cancer patients. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2460190 Fri, 05 Jun 2009 04:00:00 +0100 2460190 http://www.medworm.com/index.php?rid=2449648&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F23 Acute myeloid leukemia (AML) is a heterogenous disorder that results from a block in the differentiation of hematopoietic progenitor cells along with uncontrolled proliferation. In approximately sixty percent of cases, specific recurrent chromosomal aberrations can be identified by modern cytogenetic techniques. This cytogenetic information is the single most important tool to classify patients at their initial diagnosis into three prognostic categories: favorable, intermediate, and poor risk. Currently, favorable risk AML patients are usually treated with contemporary chemotherapy while poor risk AML patients receive allogeneic stem cell transplantation if suitable stem cell donors exist. The largest subgroup of AML patients (approximately forty percent) have no identifiable cytogenetic a... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2449648 Tue, 02 Jun 2009 04:00:00 +0100 2449648 http://www.medworm.com/index.php?rid=2449649&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F22 DNA methylation and histone acetylation are two well known epigenetic chromatin modifications. Epigenetic agents leading to DNA hypomethylation and histone hyperacetylation have been approved for treatment of hematological disorders. The first histone deacetylase inhibitor, vorinostat, has been licensed for cutaneous T cell lymphoma treatment. More than 11 new epigenetic agents are in various stages of clinical development for therapy of multiple cancer types. In this review we summarize novel histone deacetylase inhibitors and new regimens from clinical trials for epigenetic therapy of cancer. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2449649 Mon, 01 Jun 2009 04:00:00 +0100 2449649 http://www.medworm.com/index.php?rid=2429654&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F21 Cisplatin depletes MGMT and increases the sensitivity of leukemia cells to temozolomide. We performed a phase I study of cisplatin and temozolomide in patients with relapsed and refractory acute leukemia. Fifteen patients had AML, 3 had ALL, and 2 had biphenotypic leukemia. The median number of prior chemotherapy regimens was 3 (1-5). Treatment was well tolerated up to the maximal doses of temozolomide 200 mg/m2/d times 7 days and cisplatin 100 mg/m2 on day 1. There was one complete remission in this heavily pretreated patient population. Five of 20 (25%) patients demonstrated a significant reduction in bone marrow blasts. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2429654 Fri, 22 May 2009 04:00:00 +0100 2429654 http://www.medworm.com/index.php?rid=2407952&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F20 Conclusions: Phase 2 studies of ezatiostat hydrochloride liposomes for injection in MDS are supported by the tolerability and HI responses observed. An oral formulation of ezatiostat hydrochloride tablets is also in phase 2 clinical development. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2407952 Wed, 13 May 2009 04:00:00 +0100 2407952 http://www.medworm.com/index.php?rid=2371207&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F19 Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder of unknown etiology and characterized by various clinical manifestations and multiple organ involvement. It has been reported in association with POEMS syndrome and can progress to Kaposi's sarcoma or malignant lymphoma. The disease runs a more aggressive course and a poor prognosis. Optimal therapies have not been well established up to now. We here reported a case of rare MCD complicated with multiple myeloma who received bortezomib and achieved very good remission. To our knowledge, this is the first report on MCD in the setting of multiple myeloma with good response to bortezomib. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2371207 Tue, 28 Apr 2009 04:00:00 +0100 2371207 http://www.medworm.com/index.php?rid=2357832&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F18 Individualized therapies that are tailored to a patient's genetic composition will be of tremendous value for treatment of cancer. Recently, Kirsten ras (KRAS) status has emerged as a predictor of response to epidermal growth factor receptor (EGFR) targeted therapies. In this article, we will discuss targeted therapies for CRC based on EGFR signaling pathway and review published data about the potential usefulness of KRAS as a biological marker for response to these therapies. Results from relevant studies published since 2005 and unpublished results presented at national meetings were retrieved and summarized. These studies reflected response (or lack of response) to EGFR-targeted therapies in patients with metastatic CRC as a function of KRAS status. It has become clear that patients wit... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2357832 Wed, 22 Apr 2009 04:00:00 +0100 2357832 http://www.medworm.com/index.php?rid=2350711&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F17 In this study, quantitative serum Hp levels were shown to be related to cGVHD development. Further, the data suggest the possibility that specific Hp polymorphisms may be associated with cGVHD development and warrant further investigation. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2350711 Mon, 20 Apr 2009 04:00:00 +0100 2350711 http://www.medworm.com/index.php?rid=2309174&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F16 Conclusion: Our experience suggests that multi-session radiosurgery for the treatment of malignant skull base tumors is comparable to other radiosurgical techniques in progression-free survival, local tumor control, and adverse effects. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2309174 Thu, 02 Apr 2009 04:00:00 +0100 2309174 http://www.medworm.com/index.php?rid=2309176&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F15 Human beta-globin disorders are relatively common genetic diseases cause by mutations in the beta-globin gene. Increasing the expression of the gamma-globin gene has great benefits in reducing complications associated with these diseases. The Oct-1 transcription factor is involved in the transcriptional regulation of the gamma-globin gene. The human gamma-globin genes (both A-gamma and G-gamma-globin genes) carry three Oct-1 transcription factor consensus sequences within their promoter regions. We have studied the possibility of inducing gamma-globin gene expression using decoy oligonucleotides that target the Oct-1 transcription factor consensus sequence. A double-stranded 22bp decoy oligonucleotide containing the Oct-1 consensus sequence was synthesized. The results obtained from our in... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2309176 Fri, 27 Mar 2009 04:00:00 +0100 2309176 http://www.medworm.com/index.php?rid=2288534&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F14 Conclusion: Both R-CHOP and R-CVP protocols achieve excellent overall response. In patients with known cardiac history, omission of anthracyclines is reasonable and R-CVP provides a competitive CR rate. In younger patients with FL where cumulative cardio-toxicity may be of importance in the long term and in whom future stem cell transplantation is an option, again R-CVP may be a more appealing option. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2288534 Tue, 24 Mar 2009 04:00:00 +0100 2288534 http://www.medworm.com/index.php?rid=2269971&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F13 Conclusion: A subgroup of patients with metastatic pancreatic cancer has prolonged survival after treatment with gemcitabine. Only bilirubin and CA 19-9 levels were predictive of longer survival in this population. Further analysis of potential prognostic and predictive markers of response to treatment and survival are needed. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2269971 Mon, 16 Mar 2009 04:00:00 +0100 2269971 http://www.medworm.com/index.php?rid=2263866&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F12 Conclusion: Our case illustrates an unusual presentation of hematological malignancies as cholestatic jaundice. It also indicates the non-specific nature of CA 19-9 for pancreaticobiliary malignancies. It is the first case report of neoplastic precursor T cell lymphoblasts with unusual expression of synaptophysin. Tissue biopsy with thorough immunohistochemistry is required to differentiate precursor T-ALL/T-LBL from thymoma and small cell carcinoma. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2263866 Thu, 12 Mar 2009 04:00:00 +0100 2263866 http://www.medworm.com/index.php?rid=2263869&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F9 We have reviewed the pivotal presentations rcelated to colorectal cancer (CRC) and other gastrointestinal malignancies from 2008 annual meeting of the American Society of Clinical Oncology (ASCO). We have discussed the scientific findings and the impact on practice guidelines and ongoing clinical trials. The report on KRAS status in patients with metastatic CRC receiving epidermal growth factor receptor (EGFR) targeted antibody treatment has led to a change in National Comprehensive Cancer Network guideline that recommends only patients with wild-type KRAS tumor should receive this treatment. The results of double biologics (bevacizumab and anti-EGFR antibody) plus chemotherapy as first-line treatment in patients with metastatic CRC has shown a worse outcome than bevacizumab-based regimen.... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2263869 Mon, 23 Feb 2009 05:00:00 +0100 2263869 http://www.medworm.com/index.php?rid=2207087&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F9 We have reviewed the pivotal presentations related to colorectal cancer (CRC) and other gastrointestinal malignancy from 2008 annual meeting of the American Society of Clinical Oncology (ASCO). We have discussed the scientific findings and the impact on practice guidelines and ongoing clinical trials. The report on KRAS status in patients with metastatic CRC receiving epidermal growth factor receptor (EGFR) targeted antibody treatment has led to a change in National Comprehensive Cancer Network guideline that recommends only patients with wild-type KRAS tumor should receive this treatment. The results of double biologics (bevacizumab and anti-EGFR antibody) plus chemotherapy as 1st-line treatment in patients with metastatic CRC has shown a worse outcome than bevacizumab-based regimen. Micr... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2207087 Mon, 23 Feb 2009 05:00:00 +0100 2207087 http://www.medworm.com/index.php?rid=2207086&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F10 Resistance to imatinib in patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) has emerged as a significant clinical issue. Dasatinib is a tyrosine kinase inhibitor that has 325-fold greater in vitro activity against native BCR-ABL (breakpoint cluster region-Abelson leukemia virus) compared with imatinib and can overcome primary (intrinsic) and secondary (acquired) imatinib resistance. Here, we review the clinical profile of dasatinib in imatinib-resistant and -intolerant patients and share clinical approaches for managing adverse events (AEs) to ensure maximum patient benefit. References were obtained through literature searches on PubMed as well as from the Proceedings of Annual Meetings of the American Society of Cli... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2207086 Mon, 23 Feb 2009 05:00:00 +0100 2207086 http://www.medworm.com/index.php?rid=2151043&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F6 Conclusions: Radiation induced earlier and greater temporal changes in multiple cytokines in the pulmonary fibrosis sensitive mice. Positive correlation between blood and tissue levels suggests that blood may be used as a surrogate marker for tissue. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2151043 Mon, 02 Feb 2009 05:00:00 +0100 2151043 http://www.medworm.com/index.php?rid=2145113&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F5 Inflammation is a necessary albeit insufficient component of tumorigenesis in some cancers. Infectious agents directly implicated in tumorigenesis have been shown to induce inflammation. This process involves both the innate and adaptive components of the immune system which contribute to tumor angiogenesis, tumor tolerance and metastatic properties of neoplasms. Recently, heat-shock proteins have been identified as mediators of this inflammatory process and thus may provide a link between infection-mediated inflammation and subsequent cancer development. In this review, the role of heat-shock proteins in infection-induced inflammation and carcinogenesis will be discussed. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2145113 Fri, 30 Jan 2009 05:00:00 +0100 2145113 http://www.medworm.com/index.php?rid=2126164&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F2%2F1%2F3 Conclusion: Cell lines LOUCY and MEGAL express the recently described SET-NUP214 fusion gene. Of special note is that the formation of the SET exon 7 / NUP214 exon 18 gene transcript requires alternative splicing as the SET breakpoint is located downstream of the stop codon in exon 8. The cell lines are promising model systems for SET-NUP214 studies and should facilitate investigating cellular functions of the the SET-NUP214 protein. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2126164 Fri, 23 Jan 2009 05:00:00 +0100 2126164 http://www.medworm.com/index.php?rid=2075962&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F1%2F1%2F27 Haploidentical hematopoietic stem cell transplantation has made tremendous progress over the past 20 years and has become a feasible option for leukemia patients without a HLA identical sibling donor. The early complications of severe graft-versus-host disease (GVHD), graft failure and delayed engraftment, as well as disease recurrence have limited the use of this approach. Newer strategies have been applied and overcome some of the problems, including the use of T-cell depleted graft, "mega" dose of stem cells, intensive post-transplant immunosuppression and manipulation of the graft. These have decreased the transplant related mortality and GVHD associated with haploidentical transplantation, however, the major problems of disease relapse and infection, which related to late immune recon... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2075962 Wed, 31 Dec 2008 05:00:00 +0100 2075962 http://www.medworm.com/index.php?rid=2054100&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F1%2F1%2F26 Concurrent hemolysis in patients with vitamin B12 deficiency is a well-recognized phenomenon and has been attributed to intramedullary destruction of erythrocytes (ineffective erythropoiesis). Recent studies revealed that homocysteine increased the risk of hemolysis in vitamin B12 deficiency in vitro and there is a high frequency (30%) of vitamin B12 deficiency in asymptomatic patients with homozygous methylene tetrahydrofolate reductase (MTHFR) C677T mutation, a known cause of hyperhomocysteinemia. Here we report three patients with MTHFR mutations and vitamin B12 deficiency presenting with hemolytic anemia and severely elevated homocysteine levels. Patients demonstrated complete resolution of hemolysis with simultaneous normalization of serum homocysteine levels after vitamin B12 treatme... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=2054100 Thu, 18 Dec 2008 05:00:00 +0100 2054100 http://www.medworm.com/index.php?rid=1943986&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F1%2F1%2F22 At the plenary session of the 2008 annual meeting of the American Society of Clinical Oncology, updated results were presented from a large randomized phase III trial comparing adjuvant radiation therapy (RT) and one cycle of Carboplatin for the adjuvant treatment of Stage I seminoma. Results of this Medical Research Council (MRC) trial led its investigators to conclude that one cycle of carboplatin was equivalent in safety and efficacy and less toxic than RT. In this editorial, the trial's design, statistics, toxicity, and length of follow-up are discussed within the context of historical treatments of this disease. With a 1.3% increase in relapse rate (5.3% with carboplatin vs. 4.0% with radiation), a 3% or greater increase in relapse rate could not be excluded, the primary endpoint of t... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=1943986 Fri, 07 Nov 2008 05:00:00 +0100 1943986 http://www.medworm.com/index.php?rid=1915517&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F1%2F1%2F20 This review summarizes phase I trial results of 11 drugs presented at the American Society of Clinical Oncology meeting held in Chicago IL from May 30 to June 3rd 2008: BMS-663513, CT-322, CVX-045, GDC-0449, GRN163L, LY2181308, PF-00562271, RAV12, RTA 402, XL765, and the survivin vaccine. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=1915517 Wed, 29 Oct 2008 04:00:00 +0100 1915517 http://www.medworm.com/index.php?rid=1884092&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F1%2F1%2F17 Conclusion: For most patients, the presence of TEL-AML1 fusion gene at diagnosis suggests a favorable prognosis. The present study suggests that persistence of TEL-AML1 fusion as MRD has no additive prognostic value. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=1884092 Fri, 17 Oct 2008 04:00:00 +0100 1884092 http://www.medworm.com/index.php?rid=1841690&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F1%2F1%2F15 Imatinib was the first BCR-ABL-targeted agent approved for the treatment of patients with chronic myeloid leukemia (CML) and confers significant benefit for most patients; however, a substantial number of patients are either initially refractory or develop resistance. Point mutations within the ABL kinase domain of the BCR-ABL fusion protein are a major underlying cause of resistance. Of the known imatinib-resistant mutations, the most frequently occurring involve the ATP-binding loop (P-loop). In vitro evidence has suggested that these mutations are more oncogenic with respect to other mutations and wild type BCR-ABL. Dasatinib and nilotinib have been approved for second-line treatment of patients with CML who demonstrate resistance (or intolerance) to imatinib. Both agents have marked ac... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=1841690 Wed, 01 Oct 2008 04:00:00 +0100 1841690 http://www.medworm.com/index.php?rid=1826952&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F1%2F1%2F14 Conclusions: The results of this study show for the first time that arginase II produced by RCC cell lines depletes L-arginine resulting in decreased expression of CD3zeta. These results indicate that RCC cell lines expressing arginase II can modulate the L-arginine metabolic pathway to regulate both cell growth and T-cell function. Blocking arginase may lead to a decrease in RCC cell growth and aid in restoring immune function by increasing L-arginine availability for T-cell use. Understanding the interplay between arginase II and its interaction with the immune system may provide future therapeutic benefits to treat patients with RCC. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=1826952 Thu, 25 Sep 2008 04:00:00 +0100 1826952 http://www.medworm.com/index.php?rid=1816420&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F1%2F1%2F13 Conclusion: The slope of the regression line is greater for malignant than for benign nodules. Although, the SUVmax cutoff of 2.5 is a useful tool in the evaluation of large pulmonary nodules (>1.0 cm), it has no or minimal value in the evaluation of small pulmonary nodules (less than or equal to 1.0 cm). (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=1816420 Mon, 22 Sep 2008 04:00:00 +0100 1816420 http://www.medworm.com/index.php?rid=1705381&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F1%2F1%2F12 Conclusions: TOP2A deletion is associated with poor prognosis in ERBB2-amplified breast carcinomas. Clarification of the mechanism of this association will require additional study. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=1705381 Thu, 14 Aug 2008 04:00:00 +0100 1705381 http://www.medworm.com/index.php?rid=1661324&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F1%2F1%2F10 Conclusions: HRM is a rapid and efficient method of screening NK-AML samples for both novel and known NPM1 and FLT3 mutations. NPM1 mutations can be observed in both primary and secondary NK-AML cases. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=1661324 Tue, 29 Jul 2008 04:00:00 +0100 1661324 http://www.medworm.com/index.php?rid=1643179&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F1%2F1%2F9 Conclusions: Our findings suggested that GL-PS could induce selected monocytic leukemic cell differentiation into DCs with immuno-stimulatory function. The possible clinical impact of using this commonly used medicinal mushroom in patients with monocytic leukemia (AML-M4 and M5) deserved further investigation. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=1643179 Mon, 21 Jul 2008 04:00:00 +0100 1643179 http://www.medworm.com/index.php?rid=1556783&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F1%2F1%2F1 Journal of Hematology & Oncology aims not to specialize, rather to broaden and provide a platform for information exchange for all studies related to blood and cancer. It aims to include, not to exclude, all studies from basic research, translational research, case reports, and clinical trials. This journal allows the authors to keep the copyright so they can freely use and disseminate their articles as they please. All articles published in this journal are also archived in PubMed, PubMed Central, and other repositories. Therefore, this journal aims not to restrict, rather to make all published articles free and open to all. (Source: Journal of Hematology and Oncology) Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=1556783 Wed, 28 May 2008 04:00:00 +0100 1556783 http://www.medworm.com/index.php?rid=1556782&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F1%2F1%2F2 Background: Detection of circulating tumor cells (CTC) in the blood of cancer patients may have prognostic and predictive significance. However, background expression of 'tumor specific markers' in peripheral blood mononuclear cells (PBMC) may confound these studies. The goal of this study was to identify the origin of Cytokeratin 19 (CK19) and HER-2 signal in PBMC and suggest an approach to enhance techniques involved in detection of CTC in breast cancer patients. Methods: PBMC from healthy donors were isolated and fractionated into monocytes, lymphocytes, natural killer cells/granulocytes and epithelial populations using immunomagnetic selection and fluorescent cell-sorting for each cell type. RNA isolated from each fraction was analyzed for CK19, HER2 and Beta 2 microglobulin (B2M) usin... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=1556782 Wed, 28 May 2008 04:00:00 +0100 1556782 http://www.medworm.com/index.php?rid=1556781&cid=s_37195_19_f&fid=37195&url=http%3A%2F%2Fwww.jhoonline.org%2Fcontent%2F1%2F1%2F3 Desmoid fibromatoses are benign, slow growing fibroblastic neoplasms, arising from musculoaponeurotic stromal elements. Desmoids are characterized by local invasion, with a high rate of local recurrence and a tendency to destroy adjacent structures and organs. Desmoid fibromatoses are rare in children, and though they may occur in the head and neck region, are extremely rare in the paranasal sinuses. Here we report a case of extraabdominal desmoid fibromatosis in a seven-year-old boy involving the sphenoid sinus, one of only six published reports of desmoid fibromatosis of the paranasal sinuses. The expansile soft tissue mass eroded the walls of the sphenoid sinus as well as the posterior ethmoid air cells extending cephalad through the base of the skull. We discuss the clinicopathologic f... Journal of Hematology and Oncology journals http://www.medworm.com/rss/comments.php?id=1556781 Wed, 28 May 2008 04:00:00 +0100 1556781